Introduction to PAQR7 (G164091)

Target Name: PAQR7

NCBI ID: G164091

PAQR7

Introduction to PAQR7
PAQR7 (Progestin and AdipoQ Receptor 7) 鈥? A Promising Drug Target (or Biomarker)

In recent years, the identification of specific drug targets or biomarkers has become the focus of extensive research efforts in the field of medicine. PAQR7, a member of the progestin and adipoQ receptor family, has emerged as a potential drug target (or biomarker) for various diseases. This article aims to delve into the role of PAQR7, exploring its potential as a therapeutic target and its utility as a biomarker for diagnosis and prognosis.

PAQR7 as a Drug Target:

PAQR7 has attracted considerable attention as a viable drug target due to its diverse physiological functions and involvement in various disease pathways. As a member of the progestin and adipoQ receptor family, PAQR7 plays a crucial role in mediating metabolic and hormonal signaling cascades. Understanding the intricacies of PAQR7's biology and its signaling pathways could unlock novel therapeutic opportunities for diseases, such as obesity, diabetes, and cancer.

1. PAQR7 in Obesity:

Obesity has emerged as a global epidemic, leading to several health complications. PAQR7 has been implicated in the regulation of appetite and energy metabolism, making it an attractive target for obesity-related interventions. Studies have shown that PAQR7 knockout mice exhibit reduced adiposity and resistance to diet-induced obesity. Targeting PAQR7 could potentially alter adipose tissue development and promote weight loss, offering a new avenue for combating obesity.

2. PAQR7 in Diabetes:

Diabetes, both type 1 and type 2, significantly impacts global health and quality of life. PAQR7 has been implicated in the regulation of glucose metabolism and insulin signaling. By modulating PAQR7 activity, it might be possible to enhance insulin sensitivity and glucose homeostasis. This opens the door for the development of therapeutics targeting PAQR7 as a means to manage and treat diabetes effectively.

3. PAQR7 in Cancer:

Cancer represents an immense challenge to modern medicine; however, PAQR7 has shown promise as a potential target for anti-cancer therapies. Studies have revealed that PAQR7 expression is dysregulated in various cancer types, including breast, colon, and liver cancer. Targeting PAQR7 could potentially inhibit tumor growth, suppress metastasis, and improve the effectiveness of conventional anti-cancer treatments. Additionally, the level of PAQR7 expression could serve as a prognostic marker for patient survival and treatment response.

PAQR7 as a Biomarker:

In addition to its potential as a drug target, PAQR7 also holds promise as a biomarker for diagnostic and prognostic purposes. Biomarkers are measurable indicators of normal or abnormal biological processes and can aid in disease detection and treatment monitoring. PAQR7 expression profiles have been associated with various clinical conditions, enabling its potential use as a biomarker in multiple diseases.

1. PAQR7 as a Diagnostic Biomarker:

By measuring the levels of PAQR7 in body fluids or tissues, it could be possible to detect and diagnose certain diseases at an early stage. For example, increased PAQR7 expression has been observed in patients with certain types of cancer, suggesting its potential diagnostic utility.

2. PAQR7 as a Prognostic Biomarker:

In addition to its diagnostic potential, PAQR7 expression has also been linked to disease prognosis. For instance, decreased PAQR7 expression in breast cancer patients has been associated with poor outcomes and decreased overall survival. The use of PAQR7 as a prognostic biomarker could help identify patients who are at higher risk or would benefit from more aggressive treatment strategies.

Conclusion:

PAQR7, a member of the progestin and adipoQ receptor family, has emerged as a promising drug target and biomarker. Its involvement in various disease pathways, including obesity, diabetes, and cancer, highlights its potential as a therapeutic target. Additionally, the detection and measurement of PAQR7 expression levels hold promise as diagnostic and prognostic biomarkers in multiple diseases. Further research efforts are needed to fully unravel the complex biology of PAQR7 and explore its therapeutic and diagnostic applications better.

Protein Name: Progestin And AdipoQ Receptor Family Member 7

Functions: Plasma membrane progesterone (P4) receptor coupled to G proteins (PubMed:23763432). Seems to act through a G(i) mediated pathway (PubMed:23763432). May be involved in oocyte maturation (PubMed:12601167). Involved in neurosteroid inhibition of apoptosis (PubMed:23161870). Also binds dehydroepiandrosterone (DHEA), pregnanolone, pregnenolone and allopregnanolone (PubMed:23161870)

The "PAQR7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PAQR7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets